37 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Article Searches
Aclaris (ACRS) Stock Rises on Appointment of New Interim CEO https://www.zacks.com/stock/news/2211548/aclaris-acrs-stock-rises-on-appointment-of-new-interim-ceo?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2211548 Jan 17, 2024 - Aclaris (ACRS) appoints Neal Walker as interim CEO after current CEO, Douglas Manion, steps down from his role. Shares rise.
Reasons to Add Blueprint (BPMC) Stock to Your Portfolio Now https://www.zacks.com/stock/news/2210923/reasons-to-add-blueprint-bpmc-stock-to-your-portfolio-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2210923 Jan 16, 2024 - Here, we discuss some reasons why investing in Blueprint (BPMC) stock now may turn out to be a more prudent move than ever.
Merck (MRK) Keytruda Ok'd by FDA for Expanded Cervical Cancer Use https://www.zacks.com/stock/news/2210152/merck-mrk-keytruda-ok-d-by-fda-for-expanded-cervical-cancer-use?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2210152 Jan 15, 2024 - FDA approves Merck's (MRK) Keytruda plus chemoradiotherapy (CRT) for patients with FIGO 2014 Stage III-IVA cervical cancer based on data from the phase KEYNOTE-A18 study.
Regeneron (REGN) Is Up 3.97% in One Week: What You Should Know https://www.zacks.com/stock/news/2209670/regeneron-regn-is-up-3-97-in-one-week-what-you-should-know?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_10-2209670 Jan 12, 2024 - Does Regeneron (REGN) have what it takes to be a top stock pick for momentum investors? Let's find out.
Biotech Stock Roundup: REGN Down on Eylea Update, MRNA Gains on Preliminary Results https://www.zacks.com/stock/news/2208960/biotech-stock-roundup-regn-down-on-eylea-update-mrna-gains-on-preliminary-results?cid=CS-ZC-FT-analyst_blog|stock_roundup-2208960 Jan 11, 2024 - Preliminary Q4 and 2023 results from Regeneron (REGN) and Moderna (MRNA) were key highlights this week in the biotech sector.
GSK to Buy Private Biotech, Strengthen Respiratory Pipeline https://www.zacks.com/stock/news/2208092/gsk-to-buy-private-biotech-strengthen-respiratory-pipeline?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2208092 Jan 10, 2024 - GSK's proposed acquisition of Aiolos is set to add the latter's long-acting anti-TSLP monoclonal antibody, AIO-001, to GSK's broad portfolio of respiratory products.
Select Medical (SEM) Unveils Separation Plan for Concentra https://www.zacks.com/stock/news/2205808/select-medical-sem-unveils-separation-plan-for-concentra?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2205808 Jan 04, 2024 - Select Medical (SEM) intends to separate its Concentra business in a bid to enhance shareholder value and boost growth prospects of strategically prioritized areas.
Are Medical Stocks Lagging Aclaris Therapeutics (ACRS) This Year? https://www.zacks.com/stock/news/2205668/are-medical-stocks-lagging-aclaris-therapeutics-acrs-this-year?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_1-2205668 Jan 04, 2024 - Here is how Aclaris Therapeutics (ACRS) and Regeneron (REGN) have performed compared to their sector so far this year.
Earnings Estimates Moving Higher for Regeneron (REGN): Time to Buy? https://www.zacks.com/stock/news/2205196/earnings-estimates-moving-higher-for-regeneron-regn-time-to-buy?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_8-2205196 Jan 03, 2024 - Regeneron (REGN) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Best Momentum Stocks to Buy for January 3rd https://www.zacks.com/commentary/2204746/best-momentum-stocks-to-buy-for-january-3rd?cid=CS-ZC-FT-zacks_1_rank_additions|momentum_additions-2204746 Jan 03, 2024 - SRPT, WING and REGN made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 3, 2024.

Pages: 1234

<<<Page 3